Co-Diagnostics, Inc. to Host 1st Semiannual Distributor Conference on March 26-28
March 14 2019 - 6:30AM
Business Wire
Conference hosted at U.S. corporate
headquarters to include training for distributors and end-users of
Company’s diagnostic, research, and vector-control products
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today that it
will be hosting its 1st semiannual distributor conference on March
26-28 at the Company’s headquarters in Salt Lake City, Utah.
Conference attendees already committed to attend include
government, environmental testing, and private laboratory customers
and distributors of the Company’s products. Training sessions will
showcase the advantages of the CoPrimer™ technology in varying
applications, and demonstrations of Co-Diagnostics products,
including their Logix Smart™ ZDC test for Zika, dengue, and
chikungunya, now being commercialized in regions that accept the
CE-IVD mark as valid regulatory approval. Certain attending
distributors and experts have also been invited to make
presentations related to their respective fields and areas of
influence.
Any parties or organizations interested in attending should
contact Cameron Gundry, Co-Diagnostics Head of Commercialization
(LATAM/EUR) at: c.gundry[at]codiagnostics.com.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking
statements in this release include statements regarding the (i) use
of funding proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in liquid biopsy and SNP detection,
(iv) use of the Company’s liquid biopsy tests by laboratories, (v)
capital resources and runway needed to advance the Company’s
products and markets, (vi) increased sales in the near-term, (vii)
flexibility in managing the Company’s balance sheet, (viii)
anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190314005229/en/
Company Sales Contact:Seth EganHead of International
Sales+1 801-438-1036 #2s.egan@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024